Skip to main content
Navigating complement 3 glomerulopathy (C3G)
C3, complement 3; C3G, complement 3 glomerulopathy; C3GN, complement 3 glomerulonephritis; CKD, chronic kidney disease; DDD, dense deposit disease; GN, glomerulonephritis; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; KDIGO, Kidney Disease Improving Global Outcomes; MPGN, membranoproliferative glomerulonephritis.
References: 1. C3 glomerulopathy: dense deposit disease and C3 glomerulonephritis. National Organization for Rare Disorders (NORD). Accessed September 24, 2022. 2. Martin B, Smith RJH. C3 glomerulopathy. In: Adam MP, Mirzaa GM, Pagon RA, et al, eds. GeneReviews [Internet]. University of Washington; 2007. Updated April 5, 2018. Accessed July 28, 2022. 3. Smith RJH, Appel GB, Blom AM, et al. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019;15(3):129-143. 4. Hou J, Markowitz GS, Bomback AS, et al. Toward a working definition of C3 glomerulopathy: a rare renal disease. Int J Mol Sci. 2020;21(2):525. doi:10.3390/ijms21020525 5. Schena FP, Esposito P, Rossini M. A narrative review on C3 glomerulopathy: a rare renal disease. Int J Mol Sci. 2020;21(2):525. doi:10.3390/ijms21020525 6. Medjeral-Thomas NR, O’Shaughnessy MM, O’Regan JA, et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol. 2014;9(1):46-53. 7. Sethi S, De Vriese AS, Fervenza FC. Acute glomerulonephritis. Lancet. 2022;399(10335):1646-1663. 8. Gutierrez E, Praga M, Rivera F; Spanish Registry of Glomerulonephritis. Changes in the clinical presentation of immunoglobulin A nephropathy: data from the Spanish Registry of Glomerulonephritis. Nephrol Dial Transplant. 2018;33(3):472-477. 9. Feldman DL, Bomback A, Nester CN. Voice of the Patient: Report of Externally Led Patient-Focused Drug Development Meeting on Complement 3 Glomerulopathy (C3G). National Kidney Foundation; 2018. 10. Smith RJH, Alexander J, Barlow PN; Dense Deposit Disease Focus Group. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol. 2007;18(9):2447-2456. 11. Centers for Disease Control and Prevention. ICD10 Coordination and Maintenance Committee Meeting Diagnosis Agenda. March 5-6, 2019, Part 2. Accessed April 11, 2023. 12. Caravaca-Fontan F, Lucientes L, Cavero T, Praga M. Update on C3 glomerulopathy: a complement-mediated disease. Nephron. 2020;144(6):272-280. 13. Harris CL. Expanding horizons in complement drug discovery: challenges and emerging strategies. Semin Immunopathol. 2018;40(1):125-140. 14. Willows JW, Brown M, Sheerin NS. The role of complement in kidney disease. Clin Med (London). 2020;20(2):156-160. 15. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I—molecular mechanisms of activation and regulation. Front Immunol. 2015;6:(262):1-30. doi:10.3389/fimmu.2015.00262 16. Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bachi V, Roumenina LT. Complement system part II: role in immunity. Front Immunol. 2015;6:(257):1-30. doi:10.3389/fimmu.2015.00257 17. Rovin BH, Adler SG, Barratt J, et al; Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(suppl4):S1-S276. 18. Davison SN, Moss AH. Supportive care: meeting the needs of patients with advanced chronic kidney disease. Clin J Am Soc Nephrol. 2016;11(10):1879-1880. 19. Chronic kidney disease: MedlinePlus medical encyclopedia. MedlinePlus. Accessed June 6, 2023. 20. Kirpalani A, Jawa N, Smoyer WE, Licht C; Midwest Pediatric Nephrology Consortium. Long-term outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis in children. Kidney Int Rep. 2020;5(12):2313-2324.